These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9297270)

  • 21. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.
    Poulsen PL
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):17-26. PubMed ID: 12692749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
    Lewis EJ; Xu X
    Diabetes Care; 2008 Feb; 31 Suppl 2():S202-7. PubMed ID: 18227486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary glycosaminoglycan and proteoglycan excretion in normoalbuminuric patients with type 1 diabetes mellitus.
    De Muro P; Fresu P; Formato M; Tonolo G; Mameli M; Maioli M; Sanna GM; Cherchi GM
    J Nephrol; 2002; 15(3):290-6. PubMed ID: 12113601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The protective effect of low molecular weight heparin on early nephropathy in diabetic rats].
    Guo H; Gan L; Yu Z
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(21):1327-9. PubMed ID: 16200729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression.
    Popławska-Kita A; Mierzejewska-Iwanowska B; Szelachowska M; Siewko K; Nikołajuk A; Kinalska I; Górska M
    Diabetes Metab Res Rev; 2008; 24(4):310-7. PubMed ID: 18273859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review.
    Li R; Xing J; Mu X; Wang H; Zhang L; Zhao Y; Zhang Y
    Drug Des Devel Ther; 2015; 9():6275-83. PubMed ID: 26664049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of sulodexide, a glycosaminoglycan, on albuminuria in diabetic patients].
    Perusicová J; Skrha J
    Vnitr Lek; 1997 Nov; 43(11):748-52. PubMed ID: 9650507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Release of endothelium-associated proteins into blood by injection of heparin in normal subjects and in patients with Type 1 diabetes.
    Myrup B; Yokoyama H; Kristiansen OP; Østergaard PB; Olivecrona T
    Diabet Med; 2004 Oct; 21(10):1135-40. PubMed ID: 15384962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of glycosaminoglycan sulodexide on albuminuria in patients with diabetes mellitus].
    Oksa A; Pontuch P; Kratochvilova H
    Bratisl Lek Listy; 1999 Sep; 100(9):486-9. PubMed ID: 10645038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.
    Gambaro G; Kinalska I; Oksa A; Pont'uch P; Hertlová M; Olsovsky J; Manitius J; Fedele D; Czekalski S; Perusicová J; Skrha J; Taton J; Grzeszczak W; Crepaldi G
    J Am Soc Nephrol; 2002 Jun; 13(6):1615-25. PubMed ID: 12039991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytokines in noninvasive diagnostics of diabetic nephropathy progression].
    Senatorski G; Paczek L; Kropiewnicka E; Bartłomiejczyk I
    Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():28-32. PubMed ID: 12621778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy.
    Ngarmukos C; Bunnag P; Kosachunhanun N; Krittiyawong S; Leelawatana R; Prathipanawatr T; Plengvidhya N; Benjasuratwong Y; Suwanwalaikorn S; Deerochanawong C; Chetthakul T; Mongkolsomlit S; Rawdaree P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S37-42. PubMed ID: 17715832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
    Packham DK; Wolfe R; Reutens AT; Berl T; Heerspink HL; Rohde R; Ivory S; Lewis J; Raz I; Wiegmann TB; Chan JC; de Zeeuw D; Lewis EJ; Atkins RC;
    J Am Soc Nephrol; 2012 Jan; 23(1):123-30. PubMed ID: 22034636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Is microalbuminuria, an early marker of clinical nephropathy, also a cardiovascular risk factor?].
    Raynaud E; Brun JF; Fédou C; Puech-Cathala AM; Pérez-Martin A; Orsetti A
    Ann Biol Clin (Paris); 1998; 56(6):671-9. PubMed ID: 9853026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Urine proteins and excretion of brush-border antigens in the early stages of diabetic nephropathy].
    Mutti A; Ghiggeri GM; Alinovi R; Bergamaschi E; Spaggiari M; Franchini I; Queirolo C; Borghetti A
    Ann Ital Med Int; 1988; 3(1):10-8. PubMed ID: 3152832
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of diabetic nephropathy. Microalbuminuria and perspectives for intervention in insulin-dependent diabetes.
    Mathiesen ER
    Dan Med Bull; 1993 Jun; 40(3):273-85. PubMed ID: 8339600
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.